Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Jun Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7973-8416; OpenAlex author ID A5007433995. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
43
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers

Papers 8

  1. Comprehensive analysis of KLF family reveals KLF6 as a promising prognostic and immune biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12935-024-03369-3↗
  2. Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials. Co-author DOI 10.1200/jco.23.02314↗
  3. Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study. Co-author DOI 10.1097/js9.0000000000000264↗
  4. Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. Co-author DOI 10.1200/jco.22.02630↗
  5. Identification of KRAS G12V associated clonal neoantigens and immune microenvironment in long-term survival of pancreatic adenocarcinoma. Last author DOI 10.1007/s00262-021-03012-4↗
  6. Long non-coding RNA LINC01133 silencing exerts antioncogenic effect in pancreatic cancer through the methylation of DKK1 promoter and the activation of Wnt sig… Co-author DOI 10.1080/15384047.2018.1529110↗
  7. EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo. Last author DOI 10.2174/1568009616666161013101657↗
  8. A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-0186↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lin Shen · 2 shared papers, 2023–2024 · strength 0.30
  2. Henghui Zhang · 2 shared papers, 2022–2023 · strength 0.26
  3. Jiayu Lin · 1 shared paper, 2024 · strength 0.20
  4. Yishu Huang · 1 shared paper, 2024 · strength 0.20
  5. Lingxi Jiang · 1 shared paper, 2024 · strength 0.20
  6. Yang Liu · 1 shared paper, 2024 · strength 0.20
  7. Pengyi Liu · 1 shared paper, 2024 · strength 0.20
  8. Baiyong Shen · 1 shared paper, 2024 · strength 0.20
  9. Min Shi · 2 shared papers, 2014–2022 · strength 0.18
  10. Changsong Qi · 1 shared paper, 2024 · strength 0.17
  11. Jun Zhou · 1 shared paper, 2024 · strength 0.17
  12. Jin Ma · 1 shared paper, 2019 · strength 0.14
  13. Jiancheng Wang · 1 shared paper, 2019 · strength 0.14
  14. Yuanchi Weng · 1 shared paper, 2019 · strength 0.14
  15. Chao Wang · 1 shared paper, 2022 · strength 0.14
  16. Chunyi Hao · 1 shared paper, 2023 · strength 0.13
  17. Ying Yuan · 1 shared paper, 2023 · strength 0.13
  18. Hongmei Zhang · 1 shared paper, 2023 · strength 0.13
  19. Lin Yang · 1 shared paper, 2023 · strength 0.13
  20. Jianming Xu · 1 shared paper, 2023 · strength 0.13
  21. Rui‐Hua Xu · 1 shared paper, 2023 · strength 0.13
  22. Qingshan Zheng · 1 shared paper, 2023 · strength 0.13
  23. Jin Li · 1 shared paper, 2023 · strength 0.13
  24. Shukui Qin · 1 shared paper, 2023 · strength 0.13
  25. Deliang Fu · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.